Novo Nordisk A/S (NYSE:NVO) Shares Down 6.1% – What’s Next?

Novo Nordisk A/S (NYSE:NVO)’s share price dropped 6.1% during mid-day trading on Tuesday . The stock traded as low as $43.80 and last traded at $44.2390. 17,950,368 shares traded hands during mid-day trading, a decline of 0% from the average daily volume of 17,988,822 shares. The stock had previously closed at $47.09.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strong Q2 performance and higher guidance: Novo Nordisk beat revenue estimates by about 10% and EPS estimates by more than 20%. Adjusted revenue increased 7% year over year, operating profit rose 11% on cost reductions, and management raised its 2026 sales and profit outlook for the second time this year. Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
• Positive Sentiment: GLP-1 demand remains a growth driver: International markets and obesity care continued to support results, while accelerating demand for the Wegovy pill contributed to the improved outlook despite U.S. pricing and competitive pressures. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: Legal protection for semaglutide: A Dutch court granted Novo a preliminary injunction against a compounded semaglutide nasal spray, requiring the product to be removed and infringing activity to stop. This could help protect sales of Novo’s approved semaglutide products. Novo Nordisk wins Dutch court injunction
• Positive Sentiment: Shareholder return: Novo declared a dividend of 0.5786 per share payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the dividend amount and market data.
• Neutral Sentiment: CEO Mike Doustdar said Novo will prioritize faster research, bolt-on acquisitions and partnerships, including AI-enabled drug discovery, while ruling out large transformative deals for now. Novo Nordisk not currently in a position to pursue large-scale M&A
• Negative Sentiment: Competitive and pipeline concerns persist: Investors focused on slightly weaker-than-expected Wegovy pill sales, lower U.S. prices, patent expirations and a setback involving CagriSema. Eli Lilly’s stronger GLP-1 growth has amplified concerns that Novo is losing momentum in the obesity-drug market. The divide between Eli Lilly and Novo Nordisk is widening

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent analyst reports. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. BMO Capital Markets restated a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $65.81.

Novo Nordisk A/S Stock Performance

The company has a 50-day simple moving average of $46.96 and a two-hundred day simple moving average of $45.12. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm has a market capitalization of $204.96 billion, a P/E ratio of 11.20, a PEG ratio of 4.03 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be given a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 42.54%.

Institutional Trading of Novo Nordisk A/S

Hedge funds and other institutional investors have recently modified their holdings of the business. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC increased its stake in Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after buying an additional 1,587 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after buying an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $314,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.